INT79692

From wiki-pain
Revision as of 09:26, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 24
Total Number 31
Disease Relevance 16.00
Pain Relevance 4.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (PPARG) enzyme binding (PPARG) DNA binding (PPARG)
lipid metabolic process (PPARG) cytoplasm (PPARG) cytosol (PPARG)
Anatomy Link Frequency
adipocytes 4
colon 2
neuronal 1
liver 1
striatum 1
PPARG (Homo sapiens)
Pain Link Frequency Relevance Heat
COX2 393 100.00 Very High Very High Very High
agonist 77 100.00 Very High Very High Very High
cINOD 44 98.96 Very High Very High Very High
Inflammation 40 98.78 Very High Very High Very High
Dopamine 1 90.64 High High
diclofenac 13 88.40 High High
Spinal cord 8 75.60 Quite High
aspirin 8 60.72 Quite High
Pain 4 52.96 Quite High
cytokine 1 46.20 Quite Low
Disease Link Frequency Relevance Heat
Repression 48 100.00 Very High Very High Very High
Cancer 497 99.96 Very High Very High Very High
Disease 60 99.40 Very High Very High Very High
Apoptosis 55 99.12 Very High Very High Very High
INFLAMMATION 76 98.78 Very High Very High Very High
Cirrhosis 24 98.56 Very High Very High Very High
Colon Cancer 445 98.28 Very High Very High Very High
Obesity 162 98.00 Very High Very High Very High
Skin Cancer 295 97.72 Very High Very High Very High
Metastasis 123 96.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There are heterozygous loss of function mutations in the gene encoding PPARgamma in tumors from approximately 10% of human colon cancer patients.
Negative_regulation (loss) of PPARgamma in colon associated with cancer and colon cancer
1) Confidence 0.59 Published 2005 Journal Carcinogenesis Section Abstract Doc Link 15564289 Disease Relevance 0.68 Pain Relevance 0
Methylation on a specific region of the promoter is strongly correlated with PPARG lack of expression in 30% of primary CRCs and with patients' poor prognosis.
Negative_regulation (lack) of PPARG
2) Confidence 0.43 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2997072 Disease Relevance 0.53 Pain Relevance 0
and reduction of H3K27me3 at the PPARG promoter as compared with control cells (Figure 4, panel F).
Negative_regulation (reduction) of PPARG
3) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.46 Pain Relevance 0
Altogether these results indicate that MeCP2, HDAC1 and EZH2 are involved in PPARG repression in colon tumorigenesis both in vivo and in vitro.


Negative_regulation (repression) of PPARG in colon associated with repression
4) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.60 Pain Relevance 0
This is the first report that shows promoter methylation to play a role in PPARG repression in tumorigenesis.
Negative_regulation (repression) of PPARG associated with repression
5) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 1.00 Pain Relevance 0
Of note, trimethylated H3K9, a marker of silenced chromatin, was enriched at the PPARG promoter and progressively depleted after epigenetic treatments, while trimethylated H3K27 was significantly reduced only by the AZA/TSA combined treatment (Figure 3, panel C).
Negative_regulation (depleted) of PPARG
6) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.22 Pain Relevance 0
In the same HTC116 cells, the PPARG promoter was particularly enriched in H3K27me3 (Figure 4, panel E).
Negative_regulation (enriched) of PPARG
7) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.38 Pain Relevance 0
Accordingly, tumor-associated inflammatory and angiogenic processes mediated by COX2 overexpression or PPARG deficiency were suggested to play a pivotal role in the biology of melanoma progression [22].
Negative_regulation (deficiency) of PPARG associated with inflammation, cancer, cox2 and skin cancer
8) Confidence 0.41 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 1.01 Pain Relevance 0.35
Moreover, expression of COX2 was suggested to be regulated by a negative feedback loop involving PPARG and NF-?
Negative_regulation (loop) of PPARG associated with cox2
9) Confidence 0.41 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 0.63 Pain Relevance 0.43
In other organs, however, for example, in primary cancers of the lung versus normal lung tissues, decreased expression levels of PPARG were found and associated with poor prognosis [16].
Negative_regulation (decreased) of PPARG in lung associated with cancer
10) Confidence 0.41 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 2.22 Pain Relevance 0.11
Inhibitors of p38MAPK and PPAR gamma agonists may be suitable agents to suppress inflammatory activation in AD.
Negative_regulation (Inhibitors) of PPAR gamma associated with inflammation, agonist and disease
11) Confidence 0.40 Published 2002 Journal Curr. Med. Chem. Section Abstract Doc Link 11860350 Disease Relevance 1.27 Pain Relevance 0.75
PPARG agonists were shown to downregulate COX2, potentiate the apoptotic effects of chemotherapeutic agents, and inhibit the growth of human melanoma cell lines in vitro [19, 20].
Negative_regulation (downregulate) of PPARG associated with agonist, cox2, skin cancer and apoptosis
12) Confidence 0.40 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 0.65 Pain Relevance 0.44
We investigated an alternative target for NSAIDs, peroxisome proliferator-activated receptor-gamma (PPARgamma), activation of which decreases cancer cell proliferation.
Negative_regulation (decreases) of PPARgamma associated with cancer and cinod
13) Confidence 0.39 Published 2002 Journal Mol. Pharmacol. Section Abstract Doc Link 11752200 Disease Relevance 0.28 Pain Relevance 0.63
Both MeCP2 and EZH2 have recently been shown to be key regulators of Pparg repression [22].
Negative_regulation (repression) of Pparg associated with repression
14) Confidence 0.38 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.71 Pain Relevance 0
Both MeCP2 and EZH2 have been reported to be involved in Pparg repression in mouse stellate cells undergoing liver fibrogenesis [22].
Negative_regulation (repression) of Pparg in liver associated with cirrhosis and repression
15) Confidence 0.38 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997072 Disease Relevance 0.42 Pain Relevance 0
Addition of 80 mM [K+] to the differentiation medium resulted in marked suppression of the AD markers PPARG and LPL on Day 7 compared to untreated cells.
Negative_regulation (suppression) of PPARG
16) Confidence 0.37 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2581599 Disease Relevance 0 Pain Relevance 0
In a randomized multi-institutional phase II trial including 76 mostly chemorefractory patients with progression of metastatic melanoma (stage IV melanoma according to AJCC criteria), we had observed a significantly prolonged progression-free survival in the group of patients that received angiostatically scheduled low-dose metronomic chemotherapy (trofosfamide) in combination with a PPARG agonist (pioglitazone) and a COX2 inhibitor (rofecoxib) compared to the group of patients who received metronomic chemotherapy alone [22].
Negative_regulation (inhibitor) of PPARG associated with agonist, cox2 and skin cancer
17) Confidence 0.35 Published 2010 Journal PPAR Research Section Body Doc Link PMC2712952 Disease Relevance 1.12 Pain Relevance 0.37
Moreover, the effect of ibuprofen on RhoA activity and neurite growth in neuronal cultures is prevented by selective PPARgamma inhibition.
Negative_regulation (inhibition) of PPARgamma in neuronal
18) Confidence 0.31 Published 2010 Journal J. Neurosci. Section Abstract Doc Link 20089905 Disease Relevance 0.12 Pain Relevance 0.15
Microtubule affinity-regulating kinase (PAR-1) family kinases, casein kinase I epsilon (CKI epsilon), and FRAT are positive regulators of the canonical WNT pathway, whereas APC, AXIN1, AXIN2, CKI alpha, NKD1, NKD2, beta TRCP1, beta TRCP2, ANKRD6, Nemo-like kinase (NLK), and peroxisome proliferator-activated receptor gamma (PPAR gamma) are negative regulators.
Negative_regulation (regulators) of peroxisome proliferator-activated receptor gamma
19) Confidence 0.30 Published 2007 Journal Clin. Cancer Res. Section Abstract Doc Link 17634527 Disease Relevance 0 Pain Relevance 0
Microtubule affinity-regulating kinase (PAR-1) family kinases, casein kinase I epsilon (CKI epsilon), and FRAT are positive regulators of the canonical WNT pathway, whereas APC, AXIN1, AXIN2, CKI alpha, NKD1, NKD2, beta TRCP1, beta TRCP2, ANKRD6, Nemo-like kinase (NLK), and peroxisome proliferator-activated receptor gamma (PPAR gamma) are negative regulators.
Negative_regulation (regulators) of PPAR gamma
20) Confidence 0.30 Published 2007 Journal Clin. Cancer Res. Section Abstract Doc Link 17634527 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox